The life cycle of extracellular vesicles in prostate cancer: from biogenesis and homing, to functional relevance
Acronym
proEVLifeCycle
Description of the granted funding
The prostate cancer Extracellular Vesicle LifeCycle (proEVLifeCycle) network is an innovative, multidisciplinary training
program focused on understanding the biology, biomarker potential and function of extracellular vesicles (EVs) to resolve
unmet clinical needs of prostate cancer (PCa). It is within this realm, that we will equip early stage researchers with the
knowledge, tools and a creative ethos to be independent scientists, leaders, and drivers of innovation. The lifecycle of EVs is
poorly understood and their potential as non-invasive biomarkers and therapy target/agents, a growing area of interest. This
research can perfectly be integrated with the high need for novel biomarkers and therapy targets for PCa. Any relief in the
burden of this disease will have major impact on the huge socio-economic problems for patients, families, caregivers and
society.
The ambitious scientific objectives are to unravel the mysteries of EV biogenesis, homing and uptake to explain how vesicles
operate in disease processes; their heterogeneity, their molecular complexity, the biological functions they drive, their local
and systemic dissemination and how these may be manipulated. Using state-of-the-art, network-wide shared model
systems, imaging and profiling tools, and systems biology, the program will enlighten the lifecycle of EVs and identify novel
EV biomarkers and PCa therapy targets to address the unmet clinical needs.
Our original network of 7 academic and 3 company beneficiaries and 11 partners, provides optimal scientific training, crosssectoral
awareness, entrepreneurship skills, communication in the modern age, extensive opportunities for mobility and
patient-facing experiences. We herein meet identified EU-skills gaps providing well-rounded and inventive experts primed for influential careers, contributing to patient well-being and economic prosperity within the EU.
Show moreStarting year
2019
End year
2023
Granted funding
GenomeScan B.V. (NL)
265 619.88 €
Participant
ANAXOMICS BIOTECH, S.L. (ES)
250 904.88 €
Participant
ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS (ES)
250 904.88 €
Participant
FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES)
250 904.88 €
Participant
AIT AUSTRIAN INSTITUTE OF TECHNOLOGY GMBH (AT)
264 207.24 €
Participant
UNIVERSITAIR MEDISCH CENTRUM UTRECHT (NL)
265 619.88 €
Participant
CARDIFF UNIVERSITY (UK)
303 172.56 €
Participant
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (NL)
265 619.88 €
Coordinator
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR)
274 802.04 €
Participant
Amount granted
2 672 562 €
Funder
European Union
Funding instrument
Marie Skłodowska-Curie Innovative Training Networks (ITN)
Framework programme
Horizon 2020 Framework Programme
Call
Programme part
EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions (5220 Fostering new skills by means of excellent initial training of researchers (5221 )
Topic
Innovative Training Networks (MSCA-ITN-2019Call ID
H2020-MSCA-ITN-2019 Other information
Funding decision number
860303
Identified topics
cancer